|
|
|
Clinical Trials: Pre-Alzheimer’s Disease
Individuals with mild cognitive impairment may be eligible for a trial evaluating the safety of a new drug that may delay or prevent the progression to Alzheimer’s disease.
Mild cognitive impairment involves memory problems, but no difficulties with daily living activities. “Some people with mild cognitive impairment will not develop Alzheimer’s,” said Julie Sugden, RN, study coordinator. About 80 percent, however—those with specific proteins in their spinal fluid — will progress to Alzheimer's disease within five years.
"The uniqueness of this study is that it aims to prevent conversion to Alzheimer's disease over time," said Piero Antuono, MD, Medical College of Wisconsin neurologist and principal investigator of the study. Froedtert & The Medical College of Wisconsin are among 70 centers around the world to test the drug, BMS-708163, sponsored by Bristol-Myers Squibb.
About 10 patients are needed for the trial. They will receive the study drug or a placebo for 24 weeks, and will be followed up for 28 weeks. Patients must have a caregiver at home who can oversee their participation.
Patients with memory problems who do not qualify for this study can still benefit from the multidisciplinary care at Froedtert & The Medical College. They may also be eligible for other trials.
Learn more about memory disorders.
Source: Froedtert Today Date: September 2009 |
|
|